These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 3367184

  • 1. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.
    Thiébaud D, Jaeger P, Jacquet AF, Burckhardt P.
    J Clin Oncol; 1988 May; 6(5):762-8. PubMed ID: 3367184
    [Abstract] [Full Text] [Related]

  • 2. Oral versus intravenous AHPrBP (APD) in the treatment of hypercalcemia of malignancy.
    Thiébaud D, Portmann L, Jaeger P, Jacquet AF, Burckhardt P.
    Bone; 1986 May; 7(4):247-53. PubMed ID: 3768203
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate.
    Thiébaud D, Jaeger P, Jacquet AF, Burckhardt P.
    J Bone Miner Res; 1986 Dec; 1(6):555-62. PubMed ID: 3503561
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of tumor-induced osteolysis by APD.
    Burckhardt P, Thiébaud D, Perey L, von Fliedner V.
    Recent Results Cancer Res; 1989 Dec; 116():54-66. PubMed ID: 2762665
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Leukaemia-associated hypercalcaemia in a 10-year-old boy: effectiveness of aminohydroxypropylidene biphosphonate.
    Boudailliez BR, Pautard BJ, Sebert JL, Kremp O, Piussan CX.
    Pediatr Nephrol; 1990 Sep; 4(5):510-1. PubMed ID: 2242318
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
    Wimalawansa SJ.
    Cancer; 1994 Apr 15; 73(8):2223-30. PubMed ID: 8156530
    [Abstract] [Full Text] [Related]

  • 15. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
    Morton AR, Cantrill JA, Craig AE, Howell A, Davies M, Anderson DC.
    Br Med J (Clin Res Ed); 1988 Mar 19; 296(6625):811-4. PubMed ID: 3130925
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics.
    Oiso Y, Tomita A, Hasegawa H, Ariyoshi Y, Niinomi M, Yamamoto M, Takano T, Sakiyama N.
    Endocr J; 1994 Dec 19; 41(6):655-61. PubMed ID: 7704089
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.